Ayper Somer

Ayper Somer

Auto-generated profile, based on publicly available information

Ayper Somer

Istanbul University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
Vivien BéziatVivien Béziat
Vivien Béziat
JLJuan Li
Juan Li
JLJian-Xin Lin
Jian-Xin Lin
CMCindy S. Ma
Cindy S. Ma
PLPeng Li
Peng Li
JCJean-Laurent Casanova
Jean-Laurent Casanova
ZNF341 is a newly characterized transcription factor controlling baseline and inducible transcription of the human STAT3 gene.

7 February 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
DCDilek Yilmaz Ciftdogan
Dilek Yilmaz Ciftdogan
YKYıldız Ekemen keleş
Yıldız Ekemen keleş
BCBenhur Sirvan Cetin
Benhur Sirvan Cetin
NKNazan Dalgic Karabulut
Nazan Dalgic Karabulut
MEMelike Emiroglu
Melike Emiroglu
AKAteş Kara
Ateş Kara

1 November 2021 in Microvascular Research
Verified
Journal Article
Closed access
FÇFigen Çakmak
Figen Çakmak
ADAsuman Demirbuğa
Asuman Demirbuğa
DDDemet Demirkol
Demet Demirkol
SGSüheyla Gümüş
Süheyla Gümüş
STSelda Hançerli Törün
Selda Hançerli Törün
NANuray Aktay Ayaz
Nuray Aktay Ayaz

1 January 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
TGTUNCAY GÜNDÜZ
TUNCAY GÜNDÜZ
PTPınar Topaloğlu Tektürk
Pınar Topaloğlu Tektürk
ZYZuhal Yapici
Zuhal Yapici
MKMurat Kürtüncü
Murat Kürtüncü
ASAyper Somer
Ayper Somer
MEMefkure Eraksoy
Mefkure Eraksoy

30 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
STSelda Hançerli Törün
Selda Hançerli Törün
ÖKÖzge Kaba
Özge Kaba
NYNurhayat Yakut
Nurhayat Yakut
EKEda Kepenekli Kadayıfçı
Eda Kepenekli Kadayıfçı
MKManolya Kara
Manolya Kara
AAAli Ağaçfidan
Ali Ağaçfidan
The frequency of bacterial factors causing central nervous system infections has decreased as a result of the development of our national immunization program. In this study, it is aimed to obtain the data of our local surveillance by defining the viral etiology in cases diagnosed with meningoencephalitis for 1 year. Previously healhty 186 children, who applied with findings suggesting viral meningoencephalitis to 8 different tertiary health centers between August 2018 and August 2019, in Istanbul, were included. The cerebrospinal fluid (CSF) sample was evaluated by polymerase chain reaction. The M:F ratio was 1.24 in the patient group, whose age ranged from 1 to 216 months (mean 40.2 ± 48.7). Viral factor was detected in 26.8%. Enterovirus was the most common agent (24%) and followed by Adenovirus (22%) and HHV type 6 (22%). In the rest of the samples revealed HHV type 7 (10%), EBV (6%), CMV (6%), HSV type 1 (6%), Parvovirus (4%) and VZV (2%). The most common symptoms were fever (79%) and convulsions (45.7%). Antibiotherapy and antiviral therapy was started 48.6% and 4% respectively. Mortality and sequela rate resulted 0.53% and 3.7%, respectively. This highlights the importance of monitoring trends in encephalitis in Turkey with aview to improving pathogen diagnosis for encephalitis and rapidly identifying novel emerging encephalitis-causing pathogens that demand public health action especially in national immunisation programme.

1 March 2011 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
ASAyper Somer
Ayper Somer
STSelda H Törün
Selda H Törün
NSNuran Salman
Nuran Salman
The prevalence of invasive fungal infections is increasing and the infections are becoming a major problem in immunocompromised children and neonates. Fortunately, there has been a recent surge in the development of new antifungal agents. Caspofungin, the first licensed echinocandin, is a novel class of antifungal and is approved for use in children 3 months of age or older for the treatment of invasive candidiasis, salvage therapy for invasive aspergillosis and as empirical therapy for febrile neutropenia. This article reviews the published data on the use of caspofungin in immunocompromised children and neonates with invasive fungal infections.